Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Multi-center Phase II Study of Neoadjuvant Therapy With Sacituzumab Tirumotecan (Sac-TMT) and KL-A167 for Early-stage, High-risk ER+/HER2- Breast Cancer (NeoSaciA)

NCT07109284 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT07109284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07109284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Multi-center Phase II Study of Neoadjuvant Therapy With Sacituzumab Tirumotecan (Sac-TMT) and KL-A167 for Early-stage, High-risk ER+/HER2- Breast Cancer (NeoSaciA)
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2025
Completion date
December 31, 2030
Enrollment
55 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

er+her2- breast cancer